Safety and Efficacy of Tigecycline to Treat Multidrug-resistant Infections in Pediatrics: An Evidence Synthesis.

Background: The need for antimicrobial therapies effective against multidrug resistant organisms for children remains unmet. Tigecycline shows antibacterial activity across a broad spectrum of bacteria and is approved for treating complicated skin and skin-structure infections, complicated intra-abdominal infections and, in the United States, community-acquired bacterial pneumonia for adult patients. No blinded, randomized phase 3 tigecycline clinical trials on neonates or children have been completed or planned.

Efficacy of intravenous tigecycline in patients with complex infections: results from 14 Phase III and Phase IV clinical trials.

Background: infections, especially multidrug-resistant (MDR) infections, are a global health problem. This study aimed to describe clinical outcomes in patients with confirmed spp. isolates who were treated with tigecycline in randomized clinical trials.

Comparative bioavailability study of single-dose film-coated and sugar-coated ethionamide tablets in healthy volunteers.

Background: Ethionamide sugar-coated tablets have been reformulated to film-coated tablets to improve dissolution and stability.

Objective: The study objective was to compare the bioavailability of the film-coated (test) and sugar-coated (reference) formulations of ethionamide.

Methods: After providing informed consent and undergoing screening procedures, 40 healthy subjects were assigned to receive a single dose of ethionamide 250-mg film- or sugar-coated tablets, in randomized order, in the fasted state.